Single User License
INR 238070
Site License
INR 476140
Corporate User License
INR 714210

Service Tax Additional

select a format
Price

Single User License
USD 3500
Site License
USD 7000
Corporate User License
USD 10500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Pipeline Review, H2 2016

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Pipeline Review, H2 2016', provides in depth analysis on C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted pipeline therapeutics.

The report provides comprehensive information on the C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)

The report reviews C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics and enlists all their major and minor projects

The report assesses C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Overview 6

Therapeutics Development 7

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Products under Development by Stage of Development 7

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Products under Development by Therapy Area 8

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Products under Development by Indication 9

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Products under Development by Companies 12

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Products under Development by Universities/Institutes 14

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 20

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Companies Involved in Therapeutics Development 22

AFFiRiS AG 22

ChemoCentryx, Inc. 23

Dompe Farmaceutici S.p.A. 24

Prommune, Inc. 25

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Drug Profiles 26

avacopan-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

DF-2593A-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Drug to Antagonize C5aR for Periodontitis-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

EP-67-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Small Molecule to Target C5aR for Undisclosed Indication-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Synthetic Peptide to Antagonize C5aR for Amyotrophic Lateral Sclerosis-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Vaccine to Target C5a for Alzheimer's Disease-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Dormant Projects 37

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Discontinued Products 39

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Featured News & Press Releases 40

Jul 13, 2016: UNMC Researcher Secures $2.25 Million Grant to Fight Antibiotic Resistance 40

Jun 16, 2016: ChemoCentryx Announces Positive Top-Line Results for CCX168 from the Phase II ANCA-Associated Vasculitis CLASSIC Study and Advances Plans to Initiate Phase III Development 40

Jun 01, 2016: ChemoCentryx Receives European Medicines Agency Priority Medicines (PRIME) Designation for Accelerated Assessment of Complement 5a Receptor Inhibitor CCX168 for Treatment of Patients with ANCA-Associated Vasculitis 42

May 23, 2016: ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congress 43

Apr 28, 2016: ChemoCentryx Receives FDA Orphan Products Development Grant for Orally Administered Complement 5a Receptor Inhibitor CCX168 for Treatment of ANCA-Associated Vasculitis 45

Jan 06, 2016: ChemoCentryx Announces Positive Results in Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 46

Nov 05, 2015: ChemoCentryx Presents Phase II Results on CCX168 at the American Society of Nephrology Annual Meeting 47

Aug 19, 2015: UNMC spinoff company to test H1N1 vaccine in animal trial 48

Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis 49

Nov 20, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in Atypical Hemolytic Uremic Syndrome Treatment by the FDA 49

Nov 17, 2014: ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit In Non-Renal ANCA Vasculitis Disease Activity, In Addition To Previously Shown Kidney Disease Improvements 50

Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA 51

Jun 02, 2014: ChemoCentryx's Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit in ANCA-Associated Vasculitis Based on Birmingham Vasculitis Activity Score and Renal Disease Measurements 51

Dec 03, 2013: ChemoCentryx Announces Positive Top-Line CCX168 Phase II Data in ANCA-Associated Renal Vasculitis 52

Dec 07, 2012: Penn-Led Research Suggests A New Strategy To Prevent Or Halt Periodontal Disease 54

Appendix 56

Methodology 56

Coverage 56

Secondary Research 56

Primary Research 56

Expert Panel Validation 56

Contact Us 56

Disclaimer 57

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Mechanism of Actions, H2 2016 17

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Molecule Types, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 20

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 21

Pipeline by AFFiRiS AG, H2 2016 22

Pipeline by ChemoCentryx, Inc., H2 2016 23

Pipeline by Dompe Farmaceutici S.p.A., H2 2016 24

Pipeline by Prommune, Inc., H2 2016 25

Dormant Projects, H2 2016 37

Dormant Projects (Contd..1), H2 2016 38

Discontinued Products, H2 2016 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AFFiRiS AG, ChemoCentryx, Inc., Dompe Farmaceutici S.p.A., Prommune, Inc.

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Therapeutic Products under Development, Key Players in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Therapeutics, C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Pipeline Overview, C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Pipeline, C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com